Anesthesia Machine & Anesthesia Workstation
Welcome to the nerve center of the operating room. The anesthesia workstation, with its complex array of dials, circuits, and monitors, can seem like an intimidating beast. But what if you could master it? This comprehensive resource is your guide on a fascinating journey—from the historic, clunky elegance of the Boyle's machine to the sleek, intelligent workstations of Dräger, GE, and Mindray that define modern practice. We will demystify the physics, deconstruct the components, and build your confidence. This isn't just about learning a machine; it's about understanding your most critical partner in ensuring patient safety.
Our journey will be a methodical one. We'll start by laying a strong foundation, exploring the history and the core physics that govern every machine. From there, we'll build up your knowledge piece by piece, dissecting the classic anatomy of an anesthesia machine and mastering the circle breathing system. Only then will we leap into the modern era, comparing the sophisticated features of today's leading workstations. Each module is designed to build upon the last, transforming a daunting subject into a clear, manageable, and ultimately, masterable skill.
Levosimendan
Levosimendan is a calcium sensitizer and KATP channel opener that increases contractility without raising intracellular calcium or myocardial oxygen demand. Its active metabolite lasts ~80 hours. Ideal for low cardiac output with renal failure (no dose adjustment) or when milrinone fails. Key risks: hypotension and prolonged effects.
Milrinone

Milrinone is a PDE-3 inhibitor used in cardiac anesthesia as an inodilator—it increases contractility while reducing afterload and pulmonary vascular resistance. Ideal for right ventricular failure and β-blocked patients. Key risks: hypotension and prolonged half-life in renal failure. Avoid bolus if hypotensive or hypovolemic.
Mephentermine
Mephentermine is an indirect sympathomimetic that releases endogenous norepinephrine, increasing both heart rate (β-1) and SVR (α-1). Ideal for spinal-induced hypotension with bradycardia or low cardiac output. Longer-acting than ephedrine but risks tachyphylaxis. Avoid in tachycardic or ischemic patients.
Phenylephrine

A pure alpha-1 agonist causing veno-arterial constriction. First-line for neuraxial-induced hypotension (especially obstetrics). Rapid onset (30–60 sec), short duration. Key risk: reflex bradycardia and reduced cardiac output, particularly if hypovolemic. Use boluses (40–100 mcg) or infusion (0.5–1 mcg/kg/min). Avoid as monotherapy in cardiogenic shock.
Vasopressin

Vasopressin is a vasopressor acting on V1a receptors, making it ideal for vasodilatory shock (sepsis, post-bypass vasoplegia). Unlike catecholamines, it works in severe acidosis without causing tachycardia. Dose: 0.01–0.04 U/min infusion. In cardiac arrest, a single 40 U dose may be used as an alternative to epinephrine.
Succinylcholine

Succinylcholine is the fastest neuromuscular blocker (30–60s onset, 5–10min duration), ideal for RSI. Its dangers include life-threatening hyperkalemia in denervation/burns, malignant hyperthermia, bradycardia in children, and prolonged paralysis in pseudocholinesterase deficiency. Always scrutinize potassium and MH history before use.
Quantitative Neuromuscular Monitoring
Tactile evaluation of the train-of-four is unreliable—fade is undetectable until the ratio falls below 0.4. Quantitative monitors provide a numeric TOF ratio, enabling objective assessment. Residual paralysis (TOF < 0.9) occurs in 30–40% of PACU patients when relying on qualitative PNS alone. Upgrade your practice. Protect your patients.
Halothane
Halothane sensitizes the heart to catecholamines, causing arrhythmias even with small epinephrine doses. It triggers malignant hyperthermia and immune-mediated hepatitis after repeat exposure. Though obsolete in high-income countries, its unique pharmacology remains heavily tested and relevant for global anesthesia practice.
Disclaimer!
The information provided on this platform, including but not limited to articles, case studies, clinical scenarios, guidelines, and multimedia content, is intended for educational and informational purposes only.
The authors and editors of this material have made every effort to ensure the accuracy of treatments, drugs, and dosage regimens that conform to currently accepted standards. However, due to continual changes in information resulting from ongoing research and clinical experience, unique aspects of individual clinical situations, as well as the potential for human error; readers must exercise personal judgment when making a clinical decision.
This website may contain third-party information or links to other internet websites. We do not control nor assume responsibility for any third-party content provided nor content on linked Internet websites.
We strongly recommend the visitors of this website to go through its Detailed 'Disclaimer' and 'Terms of Use'.
By accessing, browsing, or using this website, you acknowledge that you have read, understood, and agreed to be bound by the 'Disclaimer' and 'Terms of Use'. If you do not agree with these terms, you must NOT use this website.